RaySearch receives 510(k) clearance for RayStation® 3.5

In March RaySearch Laboratories AB announced that version 3.5 of RaySearch's
RayStation® treatment planning system had been released for clinical use.
RaySearch has now received 510(k) clearance from the FDA for RayStation® 3.5
meaning that the new features can be marketed in the US.

The most important new features are state of-the-art tools for treatment
planning of radiation therapy with electrons and protons, complementing
RayStation’s extensive tools for planning and optimization of radiation therapy
with photons. Proton Beam Design is a brand new module in RayStation® that
contains tools for treatment planning of double scattered and uniformly scanned
protons, such as a clinically approved Pencil Beam dose engine and automatic
generation of treat-and-protect beams. This is the first clinical release of
proton planning functionality in RayStation®, to be followed by many others,
such as Pencil Beam Scanning techniques and Monte Carlo dose calculations.
Electron Beam Design is another entirely new module that includes a Monte Carlo
dose engine for electron radiation therapy and tools for manual editing of beams
similar to how it is done in the 3D-CRT module.

In addition the new version contains a wide range of other new features and
improvements.

“We are of course happy that we now have a complete offering for our US
customers, with support for all treatment modalities including protons and
electrons, and support all IMRT and VMAT delivery modes with all relevant
treatment machines. This new version also includes some highly useful tools to
improve the clinical workflow and further expands our market-leading toolbox for
adaptive 4D treatments, which I believe further cements RayStation’s position as
the most advanced treatment planning system on the US market”, says Johan Löf,
CEO of RaySearch.

About RayStation®
RayStation® integrates all RaySearch’s advanced treatment planning solutions
into a flexible treatment planning system. It combines unique features such as
multi-criteria optimization tools with full support for 4D adaptive radiation
therapy. It also includes functionality such as RaySearch’s market-leading
algorithms for IMRT and VMAT optimization and highly accurate dose engines for
photon, electron and proton therapy. The system is built on the latest software
architecture and has a graphical user interface offering state-of-the-art
usability.

About RaySearch
RaySearch Laboratories is a medical technology company that develops advanced
software solutions for improved radiation therapy of cancer. RaySearch’s
products are mainly sold through license agreements with leading partners such
as Philips, Nucletron, IBA Dosimetry, Varian and Accuray. To date, 15 products
have been launched through partners and RaySearch’s software is used at over
2,000 clinics in more than 30 countries. In addition, RaySearch offers the
proprietary treatment planning system RayStation® directly to clinics. RaySearch
was founded in 2000 as a spin-off from Karolinska Institutet in Stockholm and
the company is listed in the Small Cap segment on NASDAQ OMX Stockholm.

For more information about RaySearch, visit www.raysearchlabs.com

For further information, please contact:
Johan Löf, President and CEO, RaySearch Laboratories AB
Telephone: +46 (0)8-545 061 30
johan.lof@raysearchlabs.com